Genotype-based dosage of acenocoumarol in highly-sensitive geriatric patients.
Int J Clin Pharmacol Ther
; 53(3): 206-10, 2015 Mar.
Article
em En
| MEDLINE
| ID: mdl-25669612
ABSTRACT
OBJECTIVE:
Our aim was to determinate the acenocoumarol dose requirement in highly sensitive geriatric patients, based on a minimum of genotype (VKORC1 and CYP2C9) data.METHODS:
We used a Gaussian kernel density estimation test to identify patients highly sensitive to the drug and PHARMACHIP®-Cuma test (Progenika Biopharma, SA, Grifols, Spain) to determine the CYP2C9 and VKORC1 genotype.RESULTS:
All highly sensitive geriatric patients were taking ≤5.6 mg/week of acenocoumarol (AC), and 86% of these patients presented the following genotypes CYP2C9*1/*3 or CYP2C9*1/*2 plus VKORC1 A/G, CYP2C9*3/*3, or VKORC1 A/A.CONCLUSION:
VKORC1 A and CYP2C9*2 and/or *3 allelic variants extremely influence on AC dose requirement of highly sensitive geriatric patients. These patients display acenocoumarol dose requirement of ≤5.6 mg/week.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Envelhecimento
/
Vitamina K Epóxido Redutases
/
Citocromo P-450 CYP2C9
/
Acenocumarol
/
Anticoagulantes
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Aged80
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Int J Clin Pharmacol Ther
Assunto da revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Ano de publicação:
2015
Tipo de documento:
Article